Top Health Tech Companies in Dublin (80)
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Strong Revenue Growth: Public disclosures indicate revenue surpassed $1B in 2023 and remained above that level in 2024–2025, with 2024 noted at roughly $1.1B. These signals point to ongoing top‑line expansion.
Product Line Growth: Recent launches and releases such as IntelliCare and the 2026.1 updates for IRIS, IRIS for Health, and Health Connect highlight an active roadmap. This cadence is presented as expanding the addressable market and creating new upsell paths.
Strong Market Position & Advantage: Industry recognition places the company as a Leader in the 2026 Gartner Magic Quadrant for Enterprise EHRs and the 2025–2026 IDC MarketScape for analytical databases, alongside multiple 2026 Best in KLAS #1 rankings. These placements signal competitive strength and buyer traction in core markets.
Optum, part of the UnitedHealth Group family of businesses, is a global organization that delivers care, aided by technology to help millions of people live healthier lives. The work you do with our team will directly improve health outcomes by connecting people with the care, pharmacy benefits, data and resources they need to feel their best. Here, you will find...
.jpg)
Optum's Top Stability & Growth Strengths
Profitability: Optum generated $4.0B in operating earnings in Q2 2026 with about 160 bps year‑over‑year margin expansion, and the parent raised its 2026 adjusted EPS outlook. Operating earnings also improved at Optum Insight and Optum Rx, signaling firming margin and earnings momentum.
Cost & Operational Efficiency: Operational improvements at Optum Insight and Optum Rx’s shift toward more transparent, fee‑based pricing supported better segment profitability. Margin expansion at the Optum level despite pockets of revenue softness indicates execution on efficiency initiatives.
Innovation-Driven Growth: Optum Insight introduced new AI‑enabled offerings, and Optum closed the Alegeus acquisition to expand consumer‑directed benefits capabilities. Model changes at Optum Rx toward transparent pricing further reflect product and business model innovation.
At EMA Aesthetics we believe that life is an art and everything we do embraces that art. Our approach is avant-garde designed to challenge the status quo. We focus on combination therapy that enhances aesthetic procedures. Results over sentiment. At EMA Aesthetics we regard customers as our partners. Working together, we provide best-in-class aesthetic solutions that yield beautiful returns and...
VVater is a US-based, next-generation water treatment company that aims to provide Water for Humankind with a cornerstone of sustainability and a promise of a better, healthier tomorrow—servicing various industries and markets around the world from Real Estate, Wastewater Treatment, Municipal Potable Water, and multiple others, in particular, focusing on the recovering and recycling of different waters in a centralized...
Medserv are the leading provider of medical billing and practice management services to consultants, consultant groups and hospitals throughout Ireland and the UK. Our innovative Smartphone App allows consultants to quickly and securely send us patient information, whilst also keeping track of your claims and payments. Medserv strives to improve the management of your private practice through: - Reducing your practice administration -...
Ipsen is a French leading global mid-size biopharmaceutical company headquartered in Paris, France focusing its efforts where unmet medical needs are greatest. Ipsen develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Rare Disease and Neuroscience. We have over 5000 employees worldwide and our medicines are registered in more than 100 countries, with direct commercial presence in...
Ipsen's Top Stability & Growth Strengths
Strong Revenue Growth: Reported results show double-digit growth at constant exchange rates in 2024 and 2025 with an accelerated start in Q1 2026, and guidance indicates continued expansion in 2026. This momentum spans all three therapeutic areas rather than a single product.
Profitability: Disclosures highlight expanding core operating margins above the mid-30s and rising core operating income. Guidance continues to target strong margins alongside growth.
Diversified Revenue Streams: Recent updates indicate contributions from Oncology, Rare Disease, and Neuroscience, with products excluding Somatuline growing strongly and rare disease accelerating. Strategic acquisitions and partnerships have broadened the base beyond any single legacy brand.
We save lives by ensuring that patients get the best test first. xRefer, our smart radiology referral platform, is now live
At Output our mission is to make elite-level sports-science data simple and scalable. We specialise in providing high-value, low-burden data and insights to sports practitioners working at all levels of sport. Our single sensor V2 solution provides a 360 degree view of a weight-room and physio clinic with seamless athlete testing and tracking with a single stat of the art...
A public company, founded over 25 years ago, Consensus is the global leader in digital cloud and fax technology. Focusing in the healthcare space, we use interoperability to unify multiple systems that wouldn’t otherwise talk to each other. With exciting new initiatives on the horizon, we are continuing our strategic expansion. Read on to learn why now is the ideal...
Consensus Cloud Solutions's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyst recognition placed the company among the Leaders in worldwide digital fax, supporting a top-tier position in its core niche. Long tenure and scale around the eFax franchise plus regulated-workflow add-ons reinforce defensibility in compliance-heavy document exchange.
Healthy Cash Flow: Free cash flow increased to a record level in 2025, indicating strong cash generation even amid mixed topline performance. Operating cash flow also rose, providing flexibility to fund strategy and capital allocation.
Profitability: Adjusted EBITDA remained very high with margins around the low-50% range, signaling durable profitability. Guidance also points to continued strong earnings power alongside modest revenue growth expectations.
Eirdoc Online Doctor: Your Convenient Gateway to Quality Healthcare. Experience the ease and accessibility of online healthcare with Eirdoc Online Doctor. Our team of experienced and qualified physicians is available to provide immediate GP consultations via video or telephone, ensuring that your health remains a top priority without disrupting your busy schedule.
At Sonder, we help organisations improve the wellbeing of their people and empower them to be at their best. We do this by providing leaders with a comprehensive care platform that delivers support through the right care, at the right time. Allowing people take control of their wellbeing in a way that suits them - on their terms, on their...
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of...
Eli Lilly and Company's Top Stability & Growth Strengths
Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.
Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.
Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.
Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Viatris's Top Stability & Growth Strengths
Cost & Operational Efficiency: Cost-savings efforts are positioned as a concrete lever to support improved earnings and fund growth priorities, with an enterprise-wide program targeting substantial savings over multiple years. Guidance frames these actions as part of a broader move toward sustained revenue and earnings improvement beginning in 2026.
Resilient & Sustainable Growth: Growth is presented as re-emerging, with management guiding to a return to modest year-over-year revenue expansion in 2026 after a softer 2025. Improving quarterly trends exiting 2025 and a baseline of modest operational growth excluding divestitures support a narrative of stabilization.
Strong Market Position & Advantage: Scale and global reach are repeatedly highlighted as a stabilizing advantage, with broad geographic coverage and a large portfolio supporting access, supply reach, and competitive standing in off-patent medicines. The strategic shift toward complex generics and specialty brands is framed as reinforcing the company’s long-term positioning against pricing pressures.
Centene provides healthcare solutions to individuals across the United States with more than 23 million members nationwide.
Centene Corporation's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is rising with multiple quarters of year-over-year increases, a higher 2025 premium and service revenue outlook, and record trailing-twelve-month totals.
Strong Market Position & Advantage: The company is the largest Medicaid managed care organization and the leading ACA Marketplace carrier, with nationwide operations and sustained industry recognition.
Market Expansion: Membership is growing in the ACA Marketplace and Medicare prescription drug plans, alongside ongoing footprint expansion and key state Medicaid contract wins.
Every day, millions of patients, caregivers and providers around the world rely on Baxter’s leading portfolio of diagnostic, critical care, nutrition, kidney care, hospital and surgical products and solutions. For 90 years, we’ve been making an impact at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, therapies and...
Baxter International Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: Baxter is a leader in U.S. IV solutions and a top contender in connected-care hospital beds and surgical hemostats, underscoring durable share in core hospital categories. This positioning supports resilience despite category- and region-specific competition.
Product Line Growth: Ongoing updates to infusion technologies and continued launches in injectables and advanced surgery indicate a healthy product refresh cadence. FDA clearances and connected-care enhancements help sustain installed-base momentum.
Future-Ready Strategy: Portfolio reshaping (Kidney Care divestiture) and new leadership focused on execution and continuous improvement signal a sharpened hospital-centric strategy. Deleveraging and supply-chain initiatives aim to improve stability and long-term growth capacity.
Spectrum.Life is a mental health and wellbeing innovator on a mission to change and protect as many lives as possible; delivering digital solutions for Corporate, Insurance and University Sectors. Spectrum.Life supports 2.5m users across 2,500 clients across Ireland & the UK. Our solutions are clinically backed and ensure that there is something for everyone- for wherever they are on the...
We enable Cardiologists to save lives through exceptional decision-making accuracy
At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Listening for needs and delivering solutions. As a leader in specialty pharmaceuticals, we develop, manufacture, market and distribute innovative treatments for underserved patient populations within neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal...
Sia Partners is a next generation management consulting firm and pioneer of Consulting 4.0. We offer a unique blend of AI and design capabilities, augmenting traditional consulting to deliver superior value to our clients. Counting 1,800 consultants in 18 countries, we expect to achieve USD 300 million in turnover for the current fiscal year. With a global footprint and expertise...
Sia Partners's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Recent investment by Blackstone of up to €250 million in December 2024 provides growth capital and signals external confidence in the firm’s expansion plans. Company statements link this funding to accelerating U.S. growth, M&A, and AI-enabled offerings.
Market Expansion: Multiple acquisitions and a sustained U.S. push (e.g., Notion Consulting, Ready Set Rocket, Precedence, Kaiser Associates) indicate ongoing geographic and service-line expansion across North America and Europe. Leadership attention to the U.S. market and a growing office footprint suggest increased depth in key geographies.
Innovation-Driven Growth: The firm is productizing AI (e.g., SiaGPT and 800+ deployable AI agents by April 2026) and launching new lines like Corporate Strategy, PE & M&A, pointing to growth via differentiated, tech-enabled delivery. Partnerships and ecosystem recognition around NVIDIA and AWS reinforce momentum in AI-driven consulting.
